<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636073</url>
  </required_header>
  <id_info>
    <org_study_id>P02-CLN-028</org_study_id>
    <nct_id>NCT04636073</nct_id>
  </id_info>
  <brief_title>The Leaflex™ Early Feasibility Study</brief_title>
  <official_title>A Prospective, Multicenter, Non-randomized, Single-arm, Open-label Clinical Study to Demonstrate the Safety and Performance of the Leaflex™ Performer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pi-cardia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pi-cardia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, single-arm, early feasibility study aimed to assess safety and&#xD;
      performance of the Leaflex™ Performer in the treatment of patients with symptomatic, severe&#xD;
      aortic stenosis.&#xD;
&#xD;
      Subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12&#xD;
      months post procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in aortic valve area</measure>
    <time_frame>Baseline to 3 days</time_frame>
    <description>assessed by echo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality and all-cause stroke (VARC 2)</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of worsening of aortic regurgitation</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>by greater than 1 grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of worsening of aortic regurgitation</measure>
    <time_frame>Discharge to 30 days</time_frame>
    <description>by greater than 1 grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device related adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>distance (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>measured by KCCQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>measured by EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortic valve area</measure>
    <time_frame>30 day, 3, 6, 9, 12 months</time_frame>
    <description>assessed by echo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pressure gradients</measure>
    <time_frame>30 day, 3, 6, 9, 12 months</time_frame>
    <description>assessed by echo</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Leaflex™ Performer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Leaflex™ Performer</intervention_name>
    <description>A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.</description>
    <arm_group_label>Leaflex™ Performer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with symptomatic, severe aortic stenosis who are operable, but not recommended&#xD;
             by the heart team for immediate treatment with surgical or transcatheter aortic valve&#xD;
             replacement.&#xD;
&#xD;
          -  Patient is willing to comply with scheduled visits and tests and is able and willing&#xD;
             to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inoperable for emergency surgery.&#xD;
&#xD;
          -  Moderate or greater aortic regurgitation.&#xD;
&#xD;
          -  Anatomic contraindications.&#xD;
&#xD;
          -  Coronary, carotid, or vertebral artery disease that, in the opinion of the heart team,&#xD;
             should be treated; or treatment of coronary artery disease ≤ 1 month prior to index&#xD;
             procedure.&#xD;
&#xD;
          -  Aortic balloon valvuloplasty ≤ 3 months prior to index procedure.&#xD;
&#xD;
          -  Stroke ≤ 12 months prior to index procedure.&#xD;
&#xD;
          -  History of a myocardial infarction ≤ 6 weeks prior to index procedure.&#xD;
&#xD;
          -  Patients with clinically significant abnormality in cell blood count, history of&#xD;
             bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Hemodynamic instability.&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy with obstruction.&#xD;
&#xD;
          -  Left ventricle ejection fraction &lt;30%.&#xD;
&#xD;
          -  Ongoing severe infection, including endocarditis, or sepsis.&#xD;
&#xD;
          -  Life expectancy ≤ 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Merav Gat</last_name>
    <phone>+972 89484800</phone>
    <email>merav@pi-cardia.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlantic Health System Hospital Corp - Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

